Central Retinal Vein Occlusion Case-Control Study

American Journal of Ophthalmology

Volumn 144, Issue 6, 2007, Pages

  Koizumi, Hideki ^a,b   Ferrara, Daniela C ^a   Bruè, Claudia ^a,c   Spaide, Richard F ^a  

^a EAR AND THROAT HOSPITAL   (United States)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; WARFARIN;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLAUCOMA; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; RISK FACTOR; VASCULAR DISEASE;

EID: 36248933683     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2007.07.036     Document Type: Article

References (33)

1. The Central Vein Occlusion Study Group. Baseline and early natural history report. Arch Ophthalmol 111 (1993) 1087-1095
2. Green W.R., Chan C.C., Hutchins G.M., and Terry J.M. Central retinal vein occlusion: a prospective histopathologic study of 29 eyes in 28 cases. Retina 1 (1981) 27-55
3. Hayreh S.S. Prevalent misconceptions about acute retinal vascular occlusive disorders. Prog Retin Eye Res 24 (2005) 493-519
4. Glacet-Bernard A., Coscas G., Chabanel A., Zourdani A., Lelong F., and Samama M.M. Prognostic factors for retinal vein occlusion: prospective study of 175 cases. Ophthalmology 103 (1996) 551-560
5. Klien B.A., and Olwin J.H. A survey of the pathogenesis of retinal venous occlusion, emphasis upon choice of therapy and an analysis of the therapeutic results in fifty-three patients. AMA Arch Ophthalmol 56 (1956) 207-247
6. Hayreh S.S., Zimmerman M.B., and Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 117 (1994) 429-441
7. Mitchell P., Smith W., and Chang A. Prevalence and associations of retinal vein occlusion in Australia; the Blue Mountains Eye Study. Arch Ophthalmol 114 (1996) 1243-1247
8. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 114 (1996) 545-554
9. Rath E.Z., Frank R.N., Shin D.H., and Kim C. Risk factors for retinal vein occlusions: a case-control study. Ophthalmology 99 (1992) 509-514
10. Shahsuvaryan M.L., and Melkonyan A.K. Central retinal vein occlusion risk profile: a case-control study. Eur J Ophthalmol 13 (2003) 445-452
11. Browning D.J., and Fraser C.M. Retinal vein occlusions in patients taking warfarin. Ophthalmology 111 (2004) 1196-1200
12. Mruthyunjaya P., Wirostko W.J., Chandrashekhar R., et al. Central retinal vein occlusion in patients treated with long-term warfarin sodium (Coumadin) for anticoagulation. Retina 26 (2006) 285-291
13. Iturralde D., Spaide R.F., Meyerle C.B., et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina 26 (2006) 279-284
14. Luntz M.H., and Schenker H.I. Retinal vascular accidents in glaucoma and ocular hypertension. Surv Ophthalmol 25 (1980) 163-167
15. Appiah A.P., and Greenidge K.C. Factors associated with retinal-vein occlusion in Hispanics. Ann Ophthalmol 19 (1987) 307-309 312
16. Hirota A., Mishima H.K., and Kiuchi Y. Incidence of retinal vein occlusion at the Glaucoma Clinic of Hiroshima University. Ophthalmologica 211 (1997) 288-291
17. Hayreh S.S., Zimmerman M.B., Beri M., and Podhajsky P. Intraocular pressure abnormalities associated with central and hemicentral retinal vein occlusion. Ophthalmology 111 (2004) 133-141
18. Strahlman E.R., Quinlan P.M., Enger C., and Elman M.J. The cup-to-disc ratio and central retinal vein occlusion. Arch Ophthalmol 107 (1989) 524-525
19. Beaumont P.E., and Kang H.K. Cup-to-disc ratio, intraocular pressure, and primary open-angle glaucoma in retinal venous occlusion. Ophthalmology 109 (2002) 282-286
20. Gusek G.C., Jonas J.B., and Naumann G.O. Retinal vascular occlusions are independent of optic disk size. A morphometric study of 140 patients. Klin Monatsbl Augenheilkd 197 (1990) 14-17
21. Mansour A.M., Walsh J.B., and Henkind P. Optic disc size in central retinal vein occlusion. Ophthalmology 97 (1990) 165-166
22. Go A.S., Fang M.C., and Singer D.E. Antithrombotic therapy for stroke prevention in atrial fibrillation. Prog Cardiovasc Dis 48 (2005) 108-124
23. Goldman M.E., and Croft L.B. Atrial fibrillation: the ancient conundrum defies simple solution. J Am Coll Cardiol 45 (2005) 1813-1814
24. The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol 115 (1997) 486-491
25. Bearelly S., and Fekrat S. Controversy in the management of retinal venous occlusive disease. Int Ophthalmol Clin 44 (2004) 85-102
26. Lahey J.M., Kearney J.J., and Tunc M. Hypercoagulable states and central retinal vein occlusion. Curr Opin Pulm Med 9 (2003) 385-392
27. Tolentino M.J., Miller J.W., Gragoudas E.S., et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103 (1996) 1820-1828
28. Boyd S.R., Zachary I., Chakravarthy U., et al. Correlation of increased vascular endothelial growth factor with neovascularization and permeability in ischemic central vein occlusion. Arch Ophthalmol 120 (2002) 1644-1650
29. Tolentino M.J., McLeod D.S., Taomoto M., Otsuji T., Adamis A.P., and Lutty G.A. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 133 (2002) 373-385
30. Cursiefen C., Chen L., Borges L.P., et al. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest 113 (2004) 1040-1050
31. Zittermann S.I., and Issekutz A.C. Endothelial growth factors VEGF and bFGF differentially enhance monocyte and neutrophil recruitment to inflammation. J Leukoc Biol 80 (2006) 247-257
32. Aplin A.C., Gelati M., Fogel E., Carnevale E., and Nicosia R.F. Angiopoietin-1 and vascular endothelial growth factor induce expression of inflammatory cytokines before angiogenesis. Physiol Genomics 27 (2006) 20-28
33. Min J.K., Lee Y.M., Kim J.H., et al. Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. Circ Res 96 (2005) 300-307